期刊
CLINICAL NUCLEAR MEDICINE
卷 45, 期 1, 页码 92-93出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000002849
关键词
FDG PET; hepatocellular carcinoma; hyperprogression; immunotherapy
资金
- National Natural Science Foundation of China [81571713]
- Capital's Funds for Health Improvement and Research [2016-2-40115]
- CAMS Innovation Fund for Medical Sciences [2016-I2M-4-003, 2018I2M-3-001]
Although immunotherapy is a successful approach in oncology, it might be detrimental to some patients. In the condition of hyperprogression, patients experience accelerated progression after immunotherapy, resulting in a worse outcome. Hyperprogression may be difficult to be identified in the early stage. Once the diagnosis is confirmed in the follow-up evaluation, the immunotherapy should be stopped immediately. In this case, we report a hyperprogression patient during combined immunotherapy toward metastatic hepatocellular carcinoma observed by serial F-18-FDG PET.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据